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etermining the most appropriate revascularization strategy for patients presenting
ith unprotected left main coronary (UPLM) disease has been a topic of great recent interest.
uring this current decade, there have been multiple clinical trials and registries addressing this
ubject. Previously, UPLM disease has almost exclusively resulted in utilizing a surgical
evascularization treatment strategy. However, recent improvements in percutaneous coronary
ntervention (PCI) techniques in parallel with the benefits of drug-eluting stents (DES) to reduce
linical restenosis have enabled further investigation in catheterization-based treatment strategies
s possible alternative therapeutic options. These advances as well as an increased understanding
f both the procedural and anatomical challenges involved with complex coronary interventions
ave allowed further advancements in the field. Better adjunctive antithrombotic pharmacological
herapy in the PCI setting has favored such progress. American College of Cardiology/American
eart Association/Society for Coronary Angiography and Interventions guidelines do not
urrently endorse the performance of PCI as an appropriate alternative to surgical revascularization for
atients with UPLM disease. This paper is a review of the current evidence on UPLM PCI and
roposes future directions in this evolving field.
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October 20, 2009:1576–88 Left Main Coronary Revascularizationince its introduction over 3 decades ago, percutaneous
evascularization of “unprotected” (nonrevascularized) left
ain coronary artery disease has been considered as a
ossibly less invasive alternative to surgical bypass. How-
ver, except for patients with high surgical risk that might
reclude coronary artery bypass grafting (CABG), historical
tudies evaluating percutaneous coronary intervention (PCI)
ith balloon angioplasty or conventional bare-metal stents
ave reported at best inconsistent intermediate-term success
nd at worst unacceptably high rates of restenosis-related
omplications manifested as repeat revascularization or even
udden cardiac death. In many instances, these early dis-
ouraging reports were confounded by poor patient selection
nd still-evolving procedural technique.
Acknowledging a prior historical background of generally
nfavorable clinical outcomes and the absence of direct,
omparative trials with CABG, only modest evidence has
een available to support the indication for unprotected left
ain (UPLM) percutaneous revascularization in patients
neligible for bypass surgery with even less evidence to
ndorse PCI as an otherwise routine therapy in this indi-
ation. Accordingly, intersociety guidelines have recom-
ended against UPLM percutaneous revascularization as
n optional therapy in individuals eligible for CABG (Class
II) and support the indication with a still uncertain benefit
Class IIb) only in circumstances of excessive surgical risk
1). Similarly, a multidisciplinary committee evaluating
eneral appropriateness criteria for PCI based on practice
uidelines determined the evidence basis for UPLM percu-
aneous revascularization also did not merit its performance
s a standard treatment (2). However, in light of data
rovided by more recent clinical trials, the evidence used as
he basis to form these recommendations is now dated.
More recently, along with advances in technique, and the
ealized reduction in restenosis provided by the use of
rug-eluting stents (DES), renewed enthusiasm for
atheter-based revascularization of UPLM disease has par-
lleled the clinical achievements observed with DES in less
omplex coronary anatomy. In a lesion subset once routinely
acksonville, Florida. Dr. Kandzari receives research/grant support and consulting
onoraria from Medtronic Vascular, Inc. and Cordis Corporation. Dr. Colombo is a
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oston Scientific and Abbott Vascular. Dr. Dangas receives consulting honoraria
nd/or lecture fees from Abbott Vascular, Medtronic Vascular, Cordis Corporation,
nd Boston Scientific. Dr. Popma receives research/grant support from and serves on
dvisory boards for Medtronic Vascular, Cordis Corporation, Boston Scientific, and
bbott Vascular. Dr. Bass is on the Speakers’ Bureau for Eli-Lilly and Daiichi
ankyo.p
Manuscript received June 12, 2009; revised manuscript received July 13, 2009,
ccepted July 21, 2009.nd systematically excluded from interventional cardiology
rials, recent successes principally limited to observational
nd nonrandomized comparative trials of DES in ULPM
evascularization also support a rationale to revisit estab-
ished conventions for treatment (3). Specifically, these
tudies have demonstrated clinical equipoise between the 2
reviously contested (4–6) revascularization strategies of
CI and bypass surgery, consistently reporting similar rates
f combined safety outcomes including death, myocardial
nfarction, and stroke. New insights have also arisen from
ecent studies that have identified selected characteristics
mong patients with left main disease in whom PCI is
uggested to be an acceptable or even preferable alternative
o CABG (7–9).
Contemporary results involving revascularization with
ES demonstrate significant advances compared with ear-
ier experiences. The results from these individual studies—
hough varied in trial design, methods, and sample size—are
emarkably concordant and challenge current standards for
ppropriateness of PCI in this specific lesion subset (3,6).
et some questions remain that need to be addressed in
rder to establish UPLM PCI as an alternative revascular-
zation strategy to the existing standard of CABG:
. Beyond the issue of relevant trial design and end points,
what outstanding information must be obtained before
treatment guidelines may be advanced and UPLM PCI
should be recommended?
. Are there current, existing data that permit us to move
forward with accepting UPLM PCI as an alternative
therapy in broad patient populations or more narrowly
defined subgroups of patients?
. What nontechnical issues need to be resolved to move
this process forward, for example, long-term pharmaco-
logical therapy and other aspects of patient management?
Although not all uncertainties must be satisfied before
dvancing the indication, considering the potential clinical
mplications of UPLM restenosis or stent thrombosis,
rioritizing these details is warranted to reassure clinical
ecision-making. The purpose of this statement is to
ritically examine the available data with DES in contem-
orary UPLM revascularization, identifying existing
trengths and deficiencies in the current evidence, as well as
o determine outstanding concerns that must be satisfied
efore redefining standards for left main coronary
evascularization.
ontemporary Evidence
n UPLM Percutaneous Revascularization
uccesses and shortcomings with DES. Considering the
otential significant clinical implications of left main reste-
n
i
s
t
p
r
t
v
U
c
a
r
o
t
m
m
c
b
a
a
s
a
p
r
i
p
D
M
L
c
l
c
n
C
m
h
f
m
s
i
I
i
9
m
r
C
t
d
i
i
b
n
s
o
i
C
w
p
p
(
0
t
C
d
o
p
w
e
r
a
c
p
o
t
t
a
e
S
f
6
t
i
p
o
i
e
s
0
f
a
(
s
d
o
i
d
c
t
a
t
S
1578 Kandzari et al. JACC Vol. 54, No. 17, 2009
Left Main Coronary Revascularization October 20, 2009:1576–88osis following angioplasty and stent placement, the UPLM
ndication best represents the convergence of efficacy and
afety outcomes. Aside from 1 modest-sized randomized
rial comparing DES with bare-metal stents (10), DES
erformance in left main PCI has been evaluated in non-
andomized, observational surveys with abbreviated longi-
udinal follow-up (11–31) (Table 1). Compared with con-
entional bare-metal stents, DES revascularization in
PLM disease is associated with statistically significant and
linically meaningful reductions in angiographic restenosis
nd the need for repeat revascularization with a relative
eduction in clinical restenosis similar to that reported in
ther lesion complexities (10). These findings are consistent
hroughout all studies involving this comparison, and in
ost instances, DES-related safety outcomes of death,
yocardial infarction, and stent thrombosis do not statisti-
ally vary by direct (or more often indirect) comparison with
are-metal stents. Conclusions regarding late-term safety
nd efficacy are limited, not only by variability in trial design
nd lack of statistical power, but also according to patient
election and technique.
Encouraged by small, randomized trial experience and an
rray of observational dedicated UPLM or subgroup re-
orts, more recent clinical trials examining UPLM DES
evascularization versus CABG and comparative DES stud-
es with longer-term follow-up have provided an important
erspective regarding safety and efficacy outcomes with
ES treatment (32–44) (Table 2). The nonrandomized
AIN-COMPARE (Revascularization for Unprotected
eft Main Coronary Artery Stenosis: Comparison of Per-
utaneous Coronary Angioplasty versus Surgical Revascu-
arization) trial involving 2,240 patients with UPLM disease
ompared outcomes according to treatment with percuta-
eous revascularization (DES 71%/bare-metal stent 29%) or
ABG (43). Expectedly, population differences existed,
ost notably patients in the PCI cohort were less likely to
ave diabetes or multivessel coronary disease. Patients were
ollowed for approximately 3 years, and a propensity scoring
odel found treatment with DES was associated with a
ignificantly lower rate of freedom from repeat revascular-
zation versus CABG (90.7% vs. 98.4%, p  0.001).
mportantly, no significant differences in safety end points
ncluding freedom from death (DES 91.0% vs. CABG
3.1%, p  0.26) or the composite end point of death,
yocardial infarction, or stroke were identified. In the
andomized SYNTAX (Synergy Between Percutaneous
oronary Intervention With TAXUS and Cardiac Surgery)
rial comparing CABG with PCI for left main/multivessel
isease, patient treatment assignment was stratified accord-
ng to the presence of significant UPLM disease, represent-
ng a patient cohort (n  705) with approximately 60%
ifurcation disease and 13% isolated left main disease (i.e.,
o additional target lesions) (8). For the overall left main rubgroup, there were no differences in 1-year individual
utcomes of death or myocardial infarction, despite signif-
cantly higher rates of stroke in the CABG group (2.7%
ABG vs. 0.3% PCI, p  0.009). Repeat revascularization
as more common with PCI (6.7% CABG vs. 12.0% PCI,
 0.02) and was particularly driven by higher rates among
atients with left main disease treated for additional 2-vessel
15.3% vs. 7.7%, p  0.08) or 3-vessel (14.8% vs. 6.0%, p 
.02) disease. These findings paralleled the overall SYNTAX
rial results demonstrating no difference between PCI and
ABG for outcomes of death and myocardial infarction
espite the association of CABGwith significantly higher rates
f stroke and lower rates of repeat revascularization (45).
Implicit in recent favorable outcomes reported with
ercutaneous UPLM treatment is the consideration
hether clinical safety and efficacy are equivalent for differ-
nt DES. Given that (1) the principal benefit of DES is to
educe clinical restenosis; (2) DES vary considerably in
ngiographic outcomes (e.g., late lumen loss) but less in
linical outcome; and (3) safety differences in direct com-
arative DES trials have been inconsistent, demonstration
f DES-specific performance seems preferred over assump-
ion of class effect. At present, most DES-related UPLM
rials are limited to sirolimus- and paclitaxel-eluting stents,
nd only 1 randomized trial examining a clinical primary
nd point exists. In the ISAR-LEFTMAIN (Intracoronary
tenting and Angiographic Results: Drug-Eluting Stents
or Unprotected Coronary Left Main Lesions) trial (30),
07 patients (60% bifurcation involvement, 75% mul-
ivessel disease) were evenly assigned to UPLM revascular-
zation with sirolimus- or paclitaxel-eluting stents to com-
are by noninferiority design the 1-year composite outcome
f death, myocardial infarction, or target lesion revascular-
zation. In addition to demonstrating no significant differ-
nces in the 1-year primary end point (paclitaxel 13.6% vs.
irolimus 15.8%; relative risk: 0.85, 95% confidence interval:
.56 to 1.29), angiographic restenosis (6- to 9-month
ollow-up; paclitaxel 16.0% vs. sirolimus 19.4%, p  0.30)
nd 2-year left main-specific target lesion revascularization
paclitaxel 9.2% vs. sirolimus 10.7%, p  0.47) also did not
tatistically vary. For both stent types, the 2-year rate of
efinite stent thrombosis was 0.5%, with no new events
ccurring beyond the initial 30 days following revascular-
zation. The ISAR-LEFT MAIN trial, therefore, not only
emonstrated outcomes of death and myocardial infarction
onsistent with other DES-related trials, but also confirmed
he comparative effectiveness in the UPLM indication
mong 2 commonly used DES designs. In particular, similar
o the findings reported in the MAIN-COMPARE and
YNTAX trials, no signal suggesting an increased safety
isk with DES UPLM PCI strategy was detected.
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October 20, 2009:1576–88 Left Main Coronary Revascularizationonsiderations for UPLM
ercutaneous Revascularization
natomic lesion complexity and technique. Similar to
ategorical PCI qualifiers such as diabetes or acute myocar-
ial infarction, not all left main revascularization is alike,
nd yet clinical outcomes may vary more according to left
ain complexity than any other lesion type or clinical
haracteristic. In particular, lesion location appears to be of
aramount importance. Left main lesions not involving the
istal bifurcation (representing 40% of patients undergo-
ng revascularization) are associated with high procedural
uccess rates and favorable late-term outcomes of death,
yocardial infarction, and repeat revascularization. In a
ulticenter study of 147 patients undergoing ostial or shaft
PLM percutaneous revascularization with DES, the rates
f cardiac death and repeat target lesion revascularization
ere 2.7% and 0.7%, respectively, during an average
ollow-up period of approximately 2.5 years (7). In compar-
son, outcomes following DES revascularization of the more
ommon left main bifurcation lesions are technically more
hallenging, and optimal PCI strategies (e.g., bare-metal
tents vs. DES, 1 vs. 2 stents) are yet to be clearly defined.
meta-analysis of 17 trials involving UPLM PCI identified
he presence of bifurcation disease as the most significant
redictor of repeat revascularization and overall major ad-
erse cardiac events (46). Furthermore, these strategies may
ary depending on different anatomical features of the entire
oronary anatomy and lesion morphology (e.g., bifurcation
ngles, differences in vessel size, and mismatch). It is not
urprising then that clinical outcomes, including both safety
nd efficacy end points, have been less encouraging when
ompared with results from DES PCI of nonbifurcation left
ain lesions (24,47). In many instances, anatomic disease
omplexity and limitations of currently available device
echnologies may not lend treatment of bifurcation disease
o fair comparisons regarding stent technique. However, it
s encouraging that several recent observational studies have
onsistently demonstrated nearly equivalent clinical out-
omes comparing single-stent bifurcation revascularization
o left main stenting for ostial or shaft disease (15,21,47–49).
otably, 1 large study reported comparatively higher rates
f cardiovascular death and target lesion revascularization
ith 2-stent treatment of bifurcation disease, including
nstances of unsuccessful provisional approaches that re-
uired additional stent placement (50).
Consistent with published results involving bifurcation
tenting in non-left main disease, preliminary results in
PLM bifurcation PCI favor a single-stent provisional
pproach compared with intentional 2-stent techniques.
owever, historically, it has not been uncommon to use
ore than 1 stent to treat the UPLM bifurcation as this
trategy has been employed in approximately 40% of cases
30,50). In such instances, the optimal 2-stent technique
e.g., crush, Culotte, V- or T-stenting) has not been retermined, since any existing comparisons are challenged
y operator and institutional preference. Although novel
edicated bifurcation stent designs are in early clinical
evelopment (51,52), there is insufficient evidence to sup-
ort their procedural and clinical superiority over existing
tandards. Alternatively, treatment of left main coronary
iameters that exceed current stent designs might otherwise
ecessitate treatment with bare-metal stents and may in-
tead favor bypass surgery in certain circumstances; whereas
estenosis risk associated with bare-metal stent placement
ay be reduced by their use in larger caliber vessels, multiple
bare-metal) stent treatment of bifurcation disease may be
ess preferred.
Left main coronary lesion complexity has clear procedural
nd clinical implications, underscoring the need for proper
valuation of both the distribution and severity of disease. In
he latter instance, hemodynamic and intravascular ultra-
ound (IVUS) assessment of left main coronary atheroscle-
otic disease has associated the functional and/or anatomic
elevance of stenosis with the need for treatment and clinical
utcome (53,54). In many circumstances, the application of
VUS may also be invaluable to optimally assess plaque
istribution, bifurcation involvement, and vessel calcifica-
ion, which are often poorly defined by angiography alone.
resence of deep concentric vessel calcification, for example,
ay represent a significant challenge to achieve optimal
tent expansion and apposition. These findings may influ-
nce decisions regarding optimal revascularization strategy
i.e., PCI vs. CABG) or stent technique. IVUS may also
rovide important information regarding stent sizing, post-
eployment stent expansion, and stent-wall apposition.
lthough more established in non-left main PCI studies,
he impact of these functional or anatomical assessments on
linical outcomes appears to be intuitively beneficial when
pplied to the left main stent group (12,55). Nevertheless,
he application of IVUS in UPLM PCI trials has been
nconsistent, with some studies reporting favorable out-
omes despite negligible use of IVUS (30).
Finally, there are no standardized recommendations ad-
ressing adjunctive procedural technical decisions such as when
nd in whom to use hemodynamic support during percutane-
us UPLM revascularization, although elective use of intra-
ortic balloon counterpulsation may prevent procedural-related
omplications in higher-risk patients (56).
tent Thrombosis and Antiplatelet Therapy
he importance of compliance with dual antiplatelet med-
cation in DES-treated patients is underscored by the
emonstrated increased stent thrombosis rates occurring in
he setting of premature drug withdrawal (57–59). In a
ecent observational survey of patients treated for UPLM
Table 1
Selected DES Trials in UPLM Revascularization
Author
Journal Year (Ref. #) n Study Duration Death
Myocardial
Infarction
Target Vessel
Revascularization MACE Comments
de Lezo et al.
Am Heart J 2004 (11)
52 SES 12 months 0 4.0% 2.0%* 4.0% Bifurcation involvement: 42%
Agostoni et al.
Am J Cardiol 2005 (12)
58 SES, PES 14 months 5.0% 3.0% 7.0% 15.5% IVUS use not associated
with improved clinical
outcomes
Chieffo et al.
Circulation 2005 (13)
85 SES or PES;
64 BMS
6 months DES 4.0%,
BMS 14.0.%
N/A DES 19.0%,
BMS 31.0%
N/A Bifurcation involvement:
81% DES, 58% BMS
Lee et al.
Cardiology 2005 (14)
35 SES, 19 PES 6 months 1.9% 0 1.9%* 3.7% No difference in
angiographic restenosis
between DES
Park et al.
J Am Coll Cardiol 2005 (15)
102 SES,
121 BMS
12 months SES 0%,
BMS 0%
SES 7.0%,
BMS 8.0%
SES 2.0%*,
BMS 17.0%*
SES 8.0%,
BMS 26.0%
Bifurcation involvement:
71% SES, 43% BMS
Valgimigli et al.
Circulation 2005 (16)
95 SES or PES,
86 BMS
12 months DES 14.0%,
BMS 16.0%
DES 4.0%,
BMS 12.0%
DES 6.0%,
BMS 12.0%
DES 14.0%,
BMS 45.0%
Bifurcation 2-stent
technique: 40% DES,
15% BMS
Wood et al.
Catheter Cardiovasc Interv 2005 (17)
61 SES or PES,
100 BMS
6 months
for DES,
12 months
for BMS
DES 0.0%,
BMS 9.0%
N/A N/A DES 13.0%,
BMS 46.0%
Only 53.4% of patients with
unprotected left main
lesions
Carrie et al.
EuroIntervention 2006 (18)
49 PES,
57 BMS
12 months PES 0.0%,
BMS 7.0%
PES 2.0%,
BMS 1.8%
PES 2.0%,
BMS 26.3%
PES 4.0%,
BMS 35.1%
8-month angiographic binary
restenosis rate 6.1% PES
vs. 35.1% BMS,
p  0.0001
Christiansen et al.
EuroIntervention 2006 (19)
46 DES,
58 BMS
6 months 29.8% N/A 9.6% 25% 74% of study population
either with acute
myocardial infarction or
inoperable candidates
Han et al.
Chin Med J 2006 (20)
176 SES or PES,
34 BMS
12 months DES 5.1%,
BMS 8.8%
DES 1.1%,
BMS 2.9%
DES 10.0%,
BMS 15.0%
DES 11.4%,
BMS 26.5%
Bifurcation involvement:
69.4%; multivessel
disease: 87.5%
Kim et al.
Am J Cardiol 2006 (21)
116 SES 18 months 0 0 5.2%* 5.2% Event-free survival
significantly higher in
single-stent group
Migliorini et al.
Catheter Cardiovasc Interv 2006 (22)
101 SES or PES 6 months 12.8% 1.0% 14.0% N/A Bifurcation involvement:
87%; additional treated
non-LM lesions: 80%
Continued on next page
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Table 1
Continued
Author
Journal Year (Ref. #) n Study Duration Death
Myocardial
Infarction
Target Vessel
Revascularization MACE Comments
Price et al.
J Am Coll Cardiol 2006 (23)
50 SES 9 months 10.0% 2.0% 38.0%* 44.0% Bifurcation involvement: 94%;
angiographic surveillance
rate, 98%
Sheiban et al.
EuroIntervention 2006 (24)
72 SES,
69 BMS
12 months SES 0.0%,
BMS 0.0%
SES 0.0%,
BMS 0.0%
SES 13.6%,
BMS 24.3%*
2 yrs: DES 17.0%,
BMS 45.0%
Use of BMS and bifurcation
disease associated with
increased adverse events
Chieffo et al.
Circulation 2007 (7)
107 SES,
40 PES
886  308
days
4.1% 3.4% 1.4%* 11.4% Study limited to
nonbifurcation UPLM
lesions
Erglis et al.
J Am Coll Cardiol 2007 (10)
Randomized;
50 PES,
50 BMS
6 months PES 2.0%,
BMS 2.0%
PES 9.0%,
BMS 14.0%
PES 2.0%,
BMS 16.0%
PES 13.0%,
BMS 30.0%
Binary restenosis: PES 6.0%
vs. BMS 22.0%,
p  0.021
Gao et al.
Am Heart J 2008 (25)
220 SES or
PES, 224
BMS
15 months DES 0.5%,
BMS 4.9%
N/A DES 5.9%,
BMS 11.6%
DES 9.5%,
BMS 16.5%
Binary restenosis: DES
16.7% vs. 31.4%,
p  0.014
Kim et al.
Am J Cardiol 2008 (26)
63 SES 11.7  7.7
months
5.0% 11.0% 16.0%* 29.0% Bifurcation involvement: 73%;
single-stent strategy in
78% of bifurcations
Meliga et al.
J Am Coll Cardiol 2008 (27)
358 SES or PES 3 yrs 9.2% 8.6% 5.8%* 32.1% 3-year cardiovascular death:
6.2% elective cases vs.
21.4% emergency cases
Palmerini et al.
Am J Cardiol 2008 (28)
1,111 DES,
342 BMS
2 yrs DES 7.8%,
BMS 19.6%
DES 3.2%,
BMS 6.7%
DES 11.8%,
BMS 16.1%
N/A Propensity score-adjusted
2-year mortality
significantly lower
with DES
Carrie et al.
EuroIntervention 2009 (29)
151 PES 12 months 4.0% 3.3% 2.0%* 10.6% 9-month angiographic binary
restenosis rate 2.3%
(n  133)
Mehilli et al.
J Am Coll Cardiol 2009 (30)
Randomized;
302 PES,
305 SES
2 yrs PES 10.4%,
SES 8.7%
PES 5.4%,
SES 4.6%
PES 9.2%,
SES 10.7%
PES 21.3%,
SES 20.6%
2-year definite stent
thrombosis: 0.3% PES,
0.7% SES; no late or very
late stent thrombosis
Tamburino et al.
Eur Heart J 2009 (31)
334 DES,
145 BMS
3 yrs DES 16.6%,
BMS 29.1%
DES 4.2%,
BMS 3.4%
DES 7.9%,
BMS 10.7%
DES 25.0%,
BMS 37.8%
Analysis limited to
nonbifurcation LM disease
*Target lesion revascularization.
BMS  bare-metal stent(s); CABG  coronary artery bypass grafting; DES  drug-eluting stent(s); IVUS  intravascular ultrasound; LM  left main; LVEF  left ventricular ejection fraction; MACE  major adverse cardiac events; N/A  not available; PES 
paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s); UPLM  unprotected left main.
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Table 2
Comparative Trials Between DES and CABG in UPLM Revascularization
Author
Journal Year (Ref. #) n
Study
Duration Death
Myocardial
Infarction
Repeat
Revascularization Stroke MACCE Comments
Chieffo et al.
Circulation 2006 (32)
107 PCI,
142 CABG
12 months PCI 2.8%,
CABG 6.4%
PCI 0.9%,
CABG 1.4%
PCI 15.8%,
CABG 3.6%
PCI 0.9%,
CABG 0.7%
N/A Significantly lower adjusted death, myocardial infarction
and stroke with PCI vs. CABG; significantly lower repeat
revascularization with CABG
Lee et al.
J Am Coll Cardiol 2006 (33)
50 PCI,
123 CABG
12 months PCI 4.0%,
CABG 15.0%
N/A PCI 13.0%,
CABG 5.0%
N/A PCI 17.0%,
CABG 25.0%
Parsonnet score, diabetes, and CABG independent
predictors of MACCE
Palmerini et al.
Am J Cardiol 2006 (34)
157 PCI,
154 CABG
430 days PCI 13.4%,
CABG 12.3%
PCI 8.3%,
CABG 4.5%
PCI 25.5%,
CABG 2.6%
N/A N/A 60% of PCI cohort treated with DES; only 68% determined
appropriate for either PCI or CABG
Palmerini et al.
Eur Heart J 2007 (35)
98 PCI,
161 CABG
2 yrs PCI 18.0%,
CABG 17.0%
PCI 4.0%,
CABG 6.0%
PCI 25.0%,
CABG 3.0%
PCI 28.8%,
CABG 9.4%
N/A Study limited to patients 75 yrs
Sanmartin et al.
Am J Cardiol 2007 (36)
96 PCI,
245 CABG
12 months PCI 5.2%,
CABG 8.4%
PCI 0.0%,
CABG 1.3%
PCI 5.2,
CABG 0.8%
PCI 0.0%,
CABG 0.8%
PCI 10.4%,
CABG 11.4%
Significantly higher 30-day MACCE with CABG (2.1% vs.
9.0%, p  0.03)
Brener et al.
Am J Cardiol 2008 (37)
97 PCI,
190 CABG
3 yrs PCI 20.0%,
CABG 15.0%
N/A N/A N/A N/A 57% of PCI cohort treated with DES ; higher EuroSCORE
and diabetes independent predictors of 3-year mortality
Buszman et al.
J Am Coll Cardiol 2008 (38)
Randomized;
52 PCI,
53 CABG
12 months PCI 1.9%,
CABG 7.5%
PCI 1.9%,
CABG 5.7%
PCI 0.0%,
CABG 3.8%
PCI 28.8%,
CABG 9.4%
PCI 30.8%,
CABG 24.5%
PCI associated with significant increase in LVEF at 12
months compared with CABG; trend toward lower
mortality with PCI at 28 month follow-up (3 vs. 7 events,
p  0.08)
Hsu et al.
Int Heart J 2008 (39)
20 PCI,
39 CABG
12 months PCI 5.0%,
CABG 20.5%
PCI 0.0%,
CABG 0%
PCI 0.0%,
CABG 10.3%
PCI 0.0%,
CABG 2.6%
PCI 5.0%,
CABG 33.3%
50% of PCI cohort treated with DES
Makikallilo et al.
Ann Med 2008 (40)
49 PCI,
238 CABG
12 months PCI 4.0%,
CABG 11.0%
PCI 2.0%,
CABG 2.0%
PCI 4.0%,
CABG 2.0%
PCI 0.0%,
CABG 5.0%
PCI 10.0%,
CABG 20.0%
LVEF 40% most significant predictor of mortality
Rodes-Cabau et al.
Circulation 2008 (41)
104 PCI,
145 CABG
23  16
months
PCI 26.3%,
CABG 12.4%
PCI 23.1%,
CABG 19.3%
PCI 9.6%,
CABG 4.8%
PCI 8.7%,
CABG 6.2%
PCI 43.3%,
CABG 35.2%
Study limited to patients 80 years; 48% DES in PCI
cohort; EuroSCORE independent predictor of MACCE
regardless of revascularization strategy
Seung et al.
N Engl J Med 2008 (43)
542 PCI,
542 CABG
3 yrs PCI 7.9%,
CABG 7.8%
N/A PCI 12.6%,
CABG 2.6%
N/A PCI 9.3%,
CABG 9.2%†
Propensity matched analysis of 396 PCI and CABG patient
pairs demonstrates no significant difference in death,
myocardial infarction, or stroke but significantly higher
repeat revascularization with DES
Wu et al.
Ann Thoracic Surg 2008 (42)
135 PCI,
135 CABG
2 yrs PCI 18.0%,
CABG 5.9%
N/A PCI 27.4%,
CABG 5.9%
N/A N/A Matched analysis of DES and CABG patients (n  56 pairs)
showed no survival difference and higher repeat
revascularization with DES
Serruys
2008 (8)
357 PCI,
348 CABG
12 months PCI 4.2%,
CABG 4.4%
PCI 4.3%,
CABG 4.1%
PCI 11.8%,
CABG 6.5%
PCI 0.3%,
CABG 2.7%
PCI 15.8%,
CABG 13.7%
No significant differences overall in MACCE or death,
myocardial infarction, or stroke; PCI associated with
significantly higher MACCE in highest SYNTAX tercile
Continued on next page
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October 20, 2009:1576–88 Left Main Coronary Revascularizationtenosis with PCI, most adverse events occurred among
atients treated with 6 months dual antiplatelet therapy,
nd the risk of cardiovascular death or myocardial infarction
as more than 4-fold greater within 90 days of clopidogrel
essation compared with later time periods (60). DES
lacement in UPLM revascularization thus represents a
arrow margin between the need for a potent antirestenotic
ffect balanced by the risk of stent thrombosis related to
elayed healing. Since stent thrombosis at any time is nearly
niformly associated with myocardial infarction, and mor-
ality rates may exceed 30% (57), its occurrence in the left
ain location could have devastating consequences. In that
egard, any measure to reduce its occurrence following
PLM PCI would be clinically meaningful and must be
onsidered when moving forward with a UPLM PCI
trategy recommendation.
Several recent multicenter registries evaluating the occur-
ence of late and very late stent thrombosis provide some
eassuring and remarkably consistent evidence to support
ES treatment in UPLM disease. In the DELFT (Drug
luting stent for LeFT main) registry, the 3-year rate of
efinite/probable stent thrombosis was 1.7%, with only 2
vents occurring after the initial 30 days (1 definite, 1
robable) (27). Similarly, a recent analysis of 731 patients
ndergoing DES revascularization for UPLM stenosis
dentified an overall 0.5% definite stent thrombosis rate with
nly 1 late event and no very late (1 year) events (61).
otably, all patients were on dual antiplatelet therapy at the
ime of the event. Two additional randomized trials have
lso compared stent thrombosis rates between DES types
nd versus symptomatic bypass graft occlusion following
ABG. In the ISAR-LEFT MAIN trial (N  607)
valuating outcomes with sirolimus- and paclitaxel-eluting
tents, the 2-year occurrence of definite stent thrombosis
as 0.5% and did not significantly vary according to stent
ype (30). Recently, the frequency of left main stent throm-
osis following DES revascularization has also been exam-
ned against the perspective of clinically relevant bypass graft
cclusion. In the left main subset of the randomized
YNTAX trial (8), the 1-year rate of stent thrombosis with
aclitaxel-eluting stents was 2.7% compared with a 3.7%
ate of clinically manifest bypass graft occlusion (p  0.49),
uggesting that the frequency of acute, thrombotic events
ay be more similar than previously recognized. Notably, in
he PCI cohort of the SYNTAX trial, stent thrombosis
utcomes are reported as any event and were not specified to
he left main target lesion.
The optimal duration of dual antiplatelet therapy in
atients with UPLM disease treated with DES remains to
e defined. Recent observational studies have inconsistentlydemonstrated a benefit of combination antiplatelet therapyT
a C B
*
C
a C
c
o
b
i
S
g
t
t
t
B
s
f
I
p
o
P
t
i
f
t
s
t
a
1
(
s
p
p
P
R
d
c
r
f
(
a
(
n
c
a
p
b
R
r
e
s
i
r
p
t
p
A
A
c
g
i
c
a
U
c
s
c
d
b
e
f
o
h
s
d
r
i
d
l
d
e
a
c
t
i
a
(
o
o
f
w
i
s
p
f
m
t
i
f
n
r
1584 Kandzari et al. JACC Vol. 54, No. 17, 2009
Left Main Coronary Revascularization October 20, 2009:1576–88ontinued beyond 6 to 12 months to reduce late-term
utcomes of death, myocardial infarction, or stent throm-
osis in non-UPLM cohorts (58,59,62–66). Current Amer-
can College of Cardiology/American Heart Association/
ociety for Coronary Angiography and Interventions
uidelines offer limited assistance regarding this very prac-
ical issue (1). Although current guidelines support long-
erm aspirin treatment and at least 1 year of thienopyridine
herapy in post-PCI patients (Class I, Level of Evidence:
), this is not specific for UPLM coronary stenting. The
upport for longer-term (1 year) dual antiplatelet therapy
ollowing DES revascularization is even less robust (Class
Ib, Level of Evidence: C). Improved strategies to ensure
atient medication compliance will also need to be devel-
ped, and it appears especially relevant following UPLM
CI to identify a minimum duration after which at least
emporary interruption of antiplatelet therapy for interven-
ng medical need may be considered safe. The utility of
unctional assays to guide most appropriate antiplatelet
reatment is similarly not clearly defined; present guidelines
uggest performance of platelet aggregation studies in pa-
ients undergoing UPLM PCI (or its clinical equivalent)
nd empirically advocate increasing the clopidogrel dose to
50 mg daily if 50% platelet aggregation is demonstrated
1). The importance of better understanding and resolving
ome of these issues will become increasingly apparent if
erformance of UPLM PCI is expected to increase in broad
opulations.
ost-Revascularization Surveillance
estenosis may still occur with DES treatment of UPLM
isease, and a surveillance strategy to optimally and effi-
iently detect this problem has not been established. Issues
elated to patient selection, purpose, and timing of
ollow-up functional stress testing, invasive angiography
Class IIa recommendation [1]), intravascular ultrasound,
nd/or noninvasive computed tomographic angiography
67) are less characterized regarding comparative effective-
ess and based more on individual clinical practice. When
linical restenosis following UPLM stenting is identified,
ppropriate treatment is also uncertain, namely whether
atients should be treated with repeat DES placement,
alloon angioplasty alone for focal disease, or CABG.
ecurrent adverse events may be more common following
epeat revascularization for UPLM in-stent restenosis; how-
ver, outcomes following CABG for this indication may be
imilar to surgery for de novo left main disease. However, it
s important to recognize that failure to have complete
esolution of these particular issues does not in itself
rohibit the advancement of UPLM PCI as an important lherapeutic alternative to bypass surgery for selected
atients.
pplication of Risk Score Models
lthough predictive models based on risk assessment are
ommonplace for varied clinical and angiographic sub-
roups in interventional cardiology, their routine application
s often less practical. Specific to UPLM PCI, the lack of
onsensus regarding a comparable surgical benchmark limits
ny method for informed risk and benefit. Nevertheless, for
PLM revascularization in which: 1) a surgical standard of
are has been historically established; and 2) both PCI and
urgical alternatives may result in divergent clinical out-
omes favoring either therapy depending upon risk, the
evelopment and widespread adoption of a predictive model
ased on clinical and angiographic characteristics seems
ssential to clinical decision-making and educated, in-
ormed consent for patients.
Until recently, estimation of procedural and clinical
utcome following percutaneous UPLM revascularization
as been limited by extrapolation of risk models from bypass
urgery for complex left main and multivessel coronary
isease (e.g., EuroSCORE, Parsonnet score [68,69]) and/or
etrospective assessment within individual trials. In most
nstances, these risk scores have more often been applied for
escriptive purposes as a reference to surgical patients with
eft main and multivessel disease rather than to prospectively
etermine clinical treatment or predict outcome. In limited
xamples, a higher EuroSCORE and presentation with
cute coronary syndromes have been associated with in-
reased risk of death, myocardial infarction, and stent
hrombosis (33,41,70–72). Although advanced age as an
ndependent variable has been inconsistently predictive of
dverse outcome (and may more closely reflect comorbidity)
41), elderly patients may especially benefit from a strategy
f percutaneous revascularization given increased peri-
perative risks such as stroke. Inflammatory biomarkers,
or example C-reactive protein, have also been associated
ith an increased likelihood for adverse outcome follow-
ng UPLM PCI (73,74), although this finding may
imply represent those individuals with high-risk clinical
resentation.
Expectedly, an emerging predictor of clinical outcome
ollowing UPLM revascularization relates to both non-left
ain disease extent and severity. Although anatomic loca-
ion of disease within the left main segment has been
dentified as an important predictor of clinical outcome
ollowing PCI, the extent, severity, and complexity of
on-left main disease may be an even greater determinant of
isk. Increasing disease burden may also indicate a higher
ikelihood for incomplete revascularization, which was sig-
n
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October 20, 2009:1576–88 Left Main Coronary Revascularizationificantly more common among PCI compared with
ABG patients within the left main subgroup of the
YNTAX trial (8).
Recent application of a coronary anatomic risk score
ased on lesion severity and extent (SYNTAX score [75])
as provided insight into both patient selection and safety
nd efficacy outcomes but must be cautiously interpreted,
iven limitations of sample size and subgroup analysis.
mong 705 patients with significant UPLM disease in the
YNTAX trial, isolated left main stenosis was identified in
nly 13% of individuals, and the increasing number of
dditional vessels treated was identified as the single inde-
endent procedural determinant of 1-year combined adverse
vents (8). For UPLM patients identified in the upper tercile
f lesion complexity represented by a SYNTAX score 33,
ompared with bypass surgery, PCI was associated with nu-
erically higher death, myocardial infarction, and stroke
10.9% PCI vs. 14.2% CABG, p  0.40) and significantly
reater repeat revascularization (17.2% vs. 4.8%, p  0.0008).
onversely, no significant differences in clinical restenosis or
he composite end point of death, myocardial infarction, and
troke were observed between treatment strategies in patients
ith low (0 to 22) and intermediate (23 to 32) SYNTAX
cores. Validation of the SYNTAX score in association with
linical risk factors, in addition to proposed UPLM-specific
odels, are evolving for UPLM PCI (76) and may possibly
xpand their clinical utility.
ercutaneous UPLM Revascularization:
s it Time? Are We Ready?
ltimately, demonstration of at least clinical equivalence in
randomized trial comparing DES and surgical revascular-
zation for UPLM disease is essential before UPLM PCI
an be uniformly adopted as a routine alternative (Class I) to
ypass surgery, although like many large, ambitious studies,
he proposal alone seems likely to be an oversimplification.
specially important is the identification of a suitable trial
opulation in addition to selection and timing of study end
oints. A clinical trial end point is implied (vs. angiographic
utcomes), and a composite end point representing safety
etrics is essential. As previously suggested for the left main
ndication, the delineation between efficacy and safety rela-
ive to PCI is less distinct. Although nonrandomized in
esign, current comparative studies of UPLM PCI versus
ABG are nevertheless consistent in reporting similar hard
linical end point event rates following risk adjustment. The
ata obtained from patients receiving DES in 2 recent
arge-scale randomized trials, SYNTAX and ISAR-LEFT
AIN, is encouraging and concordant with previously
eported experiences involving DES PCI in an UPLM
opulation. Accordingly, we must consider whether the rrimary end point of subsequent investigations should
ompare only clinical outcomes restricted to death, myocar-
ial infarction, and stroke (favoring PCI) versus the inclu-
ion of target lesion revascularization (favoring CABG).
he relative weight and clinical relevance of such heteroge-
eous end points may not be shared equally. Nevertheless,
hen revascularization is considered, the timing of end
oint ascertainment is pertinent since clinically driven re-
eat revascularization following PCI may occur earlier than
ater bypass graft failure. A future challenge will involve the
dentification of the most appropriate length for optimal
linical follow-up when comparing these treatment strate-
ies. Further, as advancing patient and lesion complexity
avors CABG, future trial designs must also consider
xclusion of highest risk patients or, alternatively, pre-
pecified comparisons according to risk score. Pre-specified
nalyses according to lesion characteristics (vessel caliber,
ifurcation involvement) and technique (provisional vs.
-stent methods) are also mandatory.
What are the existing data permitting us to accept
PLM PCI as a treatment alternative either in broad
atient populations or more narrowly defined subgroups,
nd what outstanding information must be obtained before
reatment guidelines may be advanced and UPLM PCI be
ecommended? Presently, available evidence is substantive
nough to advance guideline recommendations for nonbi-
urcation UPLM PCI to Class IIa status. We also believe
hat there is sufficient data to advance the indication for
ore complex UPLM PCI beyond the present Class III to
Class IIb recommendation in the absence of complex
oexisting multivessel disease. An additional consideration
s that such procedures are performed at centers and by
perators skilled in left main intervention, and after the
atient has had a full consultation with both a cardiac
urgeon and interventionalist. Finally, there are outstanding
ssues whose resolution would assist in moving this process
orward, such as further defining optimal adjunctive phar-
acology, examining cost-effectiveness, and better stan-
ardization of post-procedural surveillance.
onclusions
or selected patient and lesion groups, our present and
volving understanding of UPLM revascularization with
ES supports revisiting PCI as an alternative to bypass
urgery beyond existing guidelines that recommend against
ts performance. This represents an opportunity for a
eappraisal of current treatment standards. The implemen-
ation of advances in catheter-based technology will help
etter address remaining technical challenges. The issue is
ot whether UPLM PCI can be technically performed, but
ather what treatment should be performed, and how the
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onsent.
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Call for Papers Heart Failure
This is a call for submission of manuscripts dealing with Heart Failure.
In recognition of the increasing research advances and number of manuscripts submitted to
JACC on certain topics, we are planning to initiate a recurring program of expanded Focus
Issues devoted to selected topics. 
In rotation, the last issue of each month will be expanded to include additional papers related
either to Heart Failure or Heart Rhythm Disorders or Prevention/Outcomes. Thus,
four issues per year will highlight each of these subjects. The articles accepted for these issues
will be in addition to those submitted and published on these topics on a regular basis in our
regular issues. 
Heart Failure will be covered in the tenth expanded Focus Issue, and we are soliciting
manuscripts on this topic to be submitted by October 30, 2009 for publication on 
April 27, 2010. Please submit manuscripts online in the usual fashion at jaccsubmit.org.
Future solicitations will go out for papers in the areas of Heart Rhythm Disorders
and Prevention/Outcomes.
